• Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

    ソース: Nasdaq GlobeNewswire / 30 7 2024 16:30:00   America/Chicago

    DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

    Dial in* (Audio Only)Click Here
      
    Webcast:Click Here
      

    In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

    The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

    *Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.

    About Eton Pharmaceuticals

    Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

    Investor Relations:

    Lisa M. Wilson
    In-Site Communications, Inc.
    T: 212-452-2793
    E: lwilson@insitecony.com

    Source: Eton Pharmaceuticals


    Primary Logo

シェアする